STOCKHOLM, Sweden--(BUSINESS WIRE)--The Swedish company Medivir (STO:MVIRB) is commencing its first human trial with a new drug against osteoporosis. The company’s researchers have been developing the compound MIV-701 over the last five years with very promising results. MIV-701 inhibits an enzyme, cathepsin K, which degrades bone, but most probably also contributes to cartilage damage in joint diseases. Laboratory research and comprehensive preclinical studies have shown the drug to be efficacious, thereby greatly reducing degradation of bone.
